|
[1]
|
Hehir, M.K. and Silvestri, N.J. (2018) Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. Neurologic Clinics, 36, 253-260. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Rahman, M.M., Islam, M.R. and Dhar, P.S. (2023) Myasthenia Gravis in Current Status: Epidemiology, Types, Etiology, Pathophysiology, Symptoms, Diagnostic Tests, Prevention, Treatment, and Complications-Correspondence. International Journal of Surgery, 109, 78-180. [Google Scholar] [CrossRef]
|
|
[3]
|
李建萍. 《重症肌无力管理国际共识指南: 2020更新版》解读[J]. 神经病学与神经康复学杂志, 2021, 17(1): 32-38.
|
|
[4]
|
江扬清. 中西医结合: 临床内科学[M]. 北京: 人民卫生出版社, 2012: 757-765.
|
|
[5]
|
裘昌林. 中医药在重症肌无力防治中的运用心得[J]. 中国中西医结合杂志, 2018, 38(10): 1159-1160.
|
|
[6]
|
张永德, 刘晓艳. 近十年重症肌无力的中医病因病机研究概况[J]. 长春中医药大学学报, 2019, 35(5): 995-997.
|
|
[7]
|
周生花. 王松龄教授治疗重症肌无力经验[J]. 中医研究, 2021, 34(2): 77-80.
|
|
[8]
|
陈益, 蒋旭宏, 丁阳阳, 等. 裘昌林教授治疗重症肌无力危象的中医经验总结[J]. 浙江中医药大学学报, 2022, 46(5): 522-526.
|
|
[9]
|
况时祥, 况耀鋆. 重症肌无力从湿毒论治探讨[J]. 湖南中医杂志, 2013, 29(12): 5-7.
|
|
[10]
|
晏显妮, 庄昆海, 陈瑞芳, 刘小斌. 刘小斌运用补中益气汤辨治重症肌无力[J]. 山东中医杂志, 2019, 38(11): 1058-1061.
|
|
[11]
|
李颖, 王松龄, 崔艳粉. 王松龄教授治疗重症肌无力验案举隅[J]. 光明中医, 2020, 35(18): 2839-2841.
|
|
[12]
|
徐艳芳, 丁瑞丛, 谢鑫玉, 等. 基于伏邪理论探讨重症肌无力之论治[J]. 中医药临床杂志, 2022, 34(11): 2041-2044.
|
|
[13]
|
刘建辉, 况时祥. 西南地区重症肌无力中医病机特点分析[J]. 内蒙古中医药, 2017, 36(3): 41-42.
|
|
[14]
|
戴梦, 刘杰, 张辰玥, 盛昭园. 李庚和从脾肾论治重症肌无力经验析要[J]. 环球中医药, 2021, 14(8): 1469-1472.
|
|
[15]
|
章莹, 余建玮, 王飞. 基于《黄帝内经》理论谈国医大师伍炳彩辨治痿证经验[J]. 中华中医药杂志, 2020, 35(10): 4996-4998.
|
|
[16]
|
徐进. 张怀亮教授六法辨治重症肌无力临床经验[J]. 中医学报, 2017, 32(3): 376-379.
|
|
[17]
|
陈逸驰，李小玲，任现志. 基于数据统计的重症肌无力中医证型及方药分析 [J]. 世界最新医学信息文摘, 2020, 20(32): 18-19, 21.
|
|
[18]
|
金子开, 高兵, 张利达, 等. 基于古医籍探讨针灸治疗全身型重症肌无力诊疗思路[J]. 中国针灸, 2021, 41(7): 819-822.
|
|
[19]
|
缪奇祥. 梁繁荣教授针灸治疗重症肌无力经验[J]. 广西中医药大学学报, 2019, 22(3): 21-24.
|
|
[20]
|
张楠, 王海荣. 针刺治疗重症肌无力[J]. 中华针灸电子杂志, 2019, 8(4): 137-138.
|
|
[21]
|
高丽, 李壮林. 重症肌无力的发病机制及临床治疗研究进展[J]. 中外医学研究, 2019, 17(9): 173-176.
|
|
[22]
|
黄欣欣, 朱德生, 徐见容, 管阳太. 重症肌无力相关自身抗体及其检测方法的研究进展[J]. 上海交通大学学报(医学版), 2018, 38(10): 1252-1258.
|
|
[23]
|
冉昊, 刘卫彬. 2019年美国重症肌无力基金会科学会议研究热点和进展[J]. 中华神经科杂志, 2021, 54(5): 532-534.
|
|
[24]
|
Jaretzki, A., Barohn, R.J., Ernstoff, R.M., et al. (2000) Myasthenia Gravis: Recommendations for Clinical Research Standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology, 55, 16-23. [Google Scholar] [CrossRef]
|
|
[25]
|
Gilhus, N.E. and Verschuuren, J.J. (2015) Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies. The Lancet Neurology, 14, 1023-1036. [Google Scholar] [CrossRef]
|
|
[26]
|
Gilhus, N., Skeie, G., Romi, F., et al. (2016) Myasthenia Gravis—Autoantibody Characteristics and Their Implications for Therapy. Nature Reviews Neurology, 12, 259-268. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
中国免疫学会神经免疫分会. 中国重症肌无力诊断和治疗指南(2020版) [J]. 中国神经免疫学和神经病学杂志, 2021, 28(1): 1-12.
|
|
[28]
|
Li, M., Ge, F., Guo, R., et al. (2019) Do Early Prednisolone and Other Immunosuppressant Therapies Prevent Generalization in Ocular Myasthenia Gravis in Western Populations: A Systematic Review and Meta-Analysis. Therapeutic Advances in Neurological Disorders, 12. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Iijima, S. (2021) Clinical and Pathophysiologic Relevance of Autoantibodies in Neonatal Myasthenia Gravis. Pediatrics & Neonatology, 62, 581-590. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Rivner, M.H., Pasnoor, M., Dimachkie, M.M., Barohn, R.J. and Mei, L. (2018) Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. Neurologic Clinics, 36, 293-310. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
彭仕军. 神经电生理对不同临床分型的重症肌无力诊断价值研究[J]. 中西医结合心脑血管病杂志, 2018, 16(9): 1280-1282.
|
|
[32]
|
Farmakidis, C., Pasnoor, M., Dimachkie, M.M. and Barohn, R.J. (2018) Treatment of Myasthenia Gravis. Neurologic Clinics, 36, 311-337. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Prado Jr., M.B. and Adiao, K.J. (2021) Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies. Neurocritical Care, 35, 528-544. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
刘艳全. 重症肌无力治疗中糖皮质激素的应用[J]. 中国医药指南, 2020, 18(7): 118-119. [Google Scholar] [CrossRef]
|
|
[35]
|
韩雪, 王登宇, 于垚. 他克莫司联合溴吡斯的明对重症肌无力的疗效及机制探索[J]. 神经损伤与功能重建, 2020, 15(2): 120-122.
|
|
[36]
|
陈晓园, 韩世权. 探究小剂量血浆置换联合大剂量激素冲击治疗重症肌无力的临床疗效[J]. 中国现代药物应用, 2019, 13(23): 175-177.
|
|
[37]
|
赵辉. 糖皮质激素联合环磷酰胺治疗重症肌无力的疗效及安全性[J]. 临床研究, 2018, 26(6): 98-99.
|
|
[38]
|
刘刚. 免疫球蛋白联合利妥昔单抗治疗重症肌无力危象的临床研究[J]. 实用中西医结合临床, 2021, 21(9): 115-116.
|
|
[39]
|
吴科. 丙种球蛋白与泼尼松结合治疗重症肌无力对免疫功能的调节与促进症状改善的作用[J]. 医学理论与实践, 2021, 34(8): 1314-1316.
|
|
[40]
|
方君圆. 胸腺切除治疗重症肌无力的疗效及其影响因素分析[D]: [硕士学位论文]. 福州: 福建医科大学, 2021.
|
|
[41]
|
徐肖, 李劲频, 葛雪晴. 重症肌无力合并胸腺异常患者胸腺切除术后的远期疗效分析[J]. 广西医科大学学报, 2020, 37(11): 2009-2013.
|
|
[42]
|
Narayanaswami, P., Sanders, D.B., Wolfe, G., et al. (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology, 96, 114-122. [Google Scholar] [CrossRef]
|
|
[43]
|
Lee, I., Kuo, H.-C., Aban, I.B., et al. (2020) Minimal Manifestation Status and Prednisone Withdrawal in the MGTX Trial. Neurology, 95, e755-e766. [Google Scholar] [CrossRef]
|
|
[44]
|
常婷, 李柱一. 中国重症肌无力研究进展近十年回顾与展望[J]. 中国神经免疫学和神经病学杂志, 2022, 29(5): 349-355.
|
|
[45]
|
Lascano, A.M. and Lalive, P.H. (2021) Update in Immunosuppressive Therapy of Myasthenia Gravis. Autoimmunity Reviews, 20, Article ID: 102712. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
常婷, 李柱一. 重症肌无力的治疗: 期待靶向免疫治疗时代的到来[J]. 中华神经科杂志, 2022, 55(4): 271-279.
|
|
[47]
|
Rodolico, C., Nicocia, G., Damato, V., et al. (2021) Benefit and Danger from Immunotherapy in Myasthenia Gravis. Neurological Sciences, 42, 1367-1375. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Wolfe, G.I., Ward, E.S., de Haard, H., et al. (2021) IgG Regulation through FcRn Blocking: A Novel Mechanism for the Treatment of Myasthenia Gravis. Journal of the Neurological Sciences, 430, Article ID: 118074. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Mantegazza, R., Wolfe, G.I., Muppidi, S., et al. (2021) Post-Intervention Status in Patients with Refractory Myasthenia Gravis Treated with Eculizumab during REGAIN and Its Open-Label Extension. Neurology, 96, e610-e618. [Google Scholar] [CrossRef]
|
|
[50]
|
Howard Jr., J.F., Nowak, R.J., Wolfe, G.I., et al. (2020) Clinical Effects of the Self-Administered Subcutaneous Complement Inhibitor Zilucoplan in Patients with Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurology, 77, 582-592. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
谢竹霄, 刘磊, 王佳伟. 补体靶向治疗在神经系统自身免疫性疾病中的应用[J]. 中华神经科杂志, 2022, 55(5): 536-543.
|
|
[52]
|
冉宁晶, 肖文, 杨芳. 陈卫银教授治疗重症肌无力经验采撷[J]. 光明中医, 2019, 34(19): 2936-2938.
|
|
[53]
|
尹燕燕. 中西医结合治疗重症肌无力临床观察[J]. 实用中医药杂志, 2021, 37(7): 1154-1156.
|
|
[54]
|
Weng, S., Fan, Z., et al. (2020) Therapeutic Efficacy and Immunoregulatory Effect of Qiangji Jianli Capsule for Patients with Myasthenia Gravis: Study Protocol for a Series of Randomized, Controlled N-of-1 Trials. Medicine, 99, e23679. [Google Scholar] [CrossRef]
|
|
[55]
|
魏玉梅, 赵承花, 刘利荣. 自拟加味益气补肾化浊方联合溴吡斯的明与泼尼松治疗重症肌无力的临床疗效[J]. 中西医结合心脑血管病杂志, 2019, 17(8): 1268-1271.
|
|
[56]
|
林海娇. 健脾益气补髓法治疗重症肌无力的临床研究[D]: [硕士学位论文]. 长春: 长春中医药大学, 2012.
|
|
[57]
|
刘蔚. 弃杖汤联合免疫球蛋白治疗重症肌无力疗效及作用机制分析[J]. 中华中医药学刊, 2018, 36(9): 2295-2297.
|
|
[58]
|
魏东生, 罗利俊, 杨洁, 丁君, 陈晓光. 健脾益肾举陷汤联合西医常规治疗Ⅱ型重症肌无力的临床研究[J]. 河北中医, 2021, 43(2): 270-273.
|
|
[59]
|
Zhang, Y., Yu, H., Dong, R., Ji, X. and Li, F. (2021) Application Prospect of Artificial Intelligence in Rehabilitation and Management of Myasthenia Gravis. BioMed Research International, 2021, Article ID: 5592472. [Google Scholar] [CrossRef] [PubMed]
|